ACE OncoCast

In this episode, the experts discuss the latest insights on osimertinib resistance in EGFR-mutated NSCLC and promising new data on targeting MET amplification, one of the most common acquired resistance mechanisms to first-line osimertinib.

In this episode, lung cancer experts discuss the treatment approach for patients with early-stage, resectable NSCLC who  harbor EGFR sensitizing mutations. Listen to the latest clinical trial data on the use of adjuvant targeted therapy for this patient population.

In this episode, experts explore new data related to EGFR TKI resistance, specifically resistance to osimertinib. Listen to our experts evaluating the real-world data on most common resistance mechanisms to osimertinib and emerging strategies to overcome resistance. 

In this episode, our experts discuss current and new strategies for targeting KRAS G12C mutation. Hear about emerging strategies to enhance activity of current treatment options in this molecular subtype. 

In this episode two experts discuss new data presented at WCLC on targeting MET ex14 skipping mutations. Listen to the latest evidence on managing this rare molecular subtype and how these data may impact clinical practice. 

Novel strategies are needed to improve outcomes for patients with LA SCCHN. Enhancing chemoradiation by targeting Inhibitor of Apoptosis Proteins (IAPs) – a class of proteins that regulate apoptosis and modulate immune responses – is currently the most promising strategy, and a phase III clinical trial is underway. Alternative targeted therapies in combination with (chemo)radiation are also being investigated. Dr. Yungan Tao, Dr. Jonathan Schoenfeld, and Dr. Ezra Cohen review the available data for targeting IAPs and consider the future treatment landscape for patients with LA SCCHN. 

Based on improved survival, PD-1 immune checkpoint inhibitors (± chemotherapy) have become the standard of care for patients with recurrent/metastatic SCCHN. However, in patients with locally advanced disease, the results of several clinical trials evaluating the addition of PD-(L)1 inhibitors to conventional chemoradiotherapy have been disappointing. Dr. Ezra Cohen, Dr. Yungan Tao, and Dr. Jonathan Schoenfeld discuss the potential reasons for immunotherapy failure, promising neoadjuvant immunotherapy approaches, and some ongoing, eagerly awaited trials that will hopefully help to define the role of immunotherapy in LA SCCHN.

More than half of patients with head and neck cancer present with locally advanced disease, and high-risk patients continue to have a poor prognosis. The treatment of locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) is complex and requires a multidisciplinary team approach. Dr. Jonathan Schoenfeld, Dr. Ezra Cohen, and Dr. Yungan Tao discuss the current treatment strategies for these patients and challenges in achieving cure while preserving function and quality of life.

In our final episode of a series of advanced urothelial case discussions, two experts review the case of a patient with immunotherapy-related adverse events. Listen in to hear about the latest guidelines for the management of immune-related adverse events and how our experts would manage this patient.

In this penultimate episode of our podcast exploring treatment options for patients with advanced urothelial cancer, our experts discuss the latest data on immunotherapy options for cisplatin-ineligible patients. Learn when and how immunotherapy may be an appropriate treatment approach for your patients.